Although it shows no significant difference in overall survival time between patients with and without mutations in all cancer types (Fig. 7A), the potential for stratification on prognosis by RYR1 mutations was found in LUAD, adrenocortical carcinoma (ACC), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), kidney chromophobe (KICH), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML) and uterine corpus endometrial carcinoma (UCEC) (Fig. 7B–H, P < 0.1). This evidence concerns the gene RYR1 and cancer.